Promising new immunotherapy

Asbestos cancer (Mesothelioma) is caused by inhalation of asbestos fibers. The average survival after diagnosis is approximately 9 months. With the current 'standard of care' treatment (chemotherapy) that will be about 12 months. The treatment of Amphera ideally follows after this chemotherapy. The immunotherapy of Amphera is currently being investigated in a phase II / III clinical trial.

For more information see: www.amphera.nl